Zimmer Biomet Holdings, Inc. (NYSE:ZBH) was upgraded by investment analysts at Deutsche Bank AG from a “hold” rating to a “buy” rating in a research report issued on Tuesday. The brokerage currently has a $128.00 target price on the medical equipment provider’s stock. Deutsche Bank AG’s price target indicates a potential upside of 15.23% from the company’s current price.
A number of other equities analysts also recently issued reports on the company. Morgan Stanley upped their price target on Zimmer Biomet Holdings from $137.00 to $150.00 and gave the company an “overweight” rating in a report on Monday, July 17th. Zacks Investment Research downgraded Zimmer Biomet Holdings from a “hold” rating to a “sell” rating in a report on Tuesday, August 1st. BidaskClub downgraded Zimmer Biomet Holdings from a “buy” rating to a “hold” rating in a report on Monday, July 24th. Canaccord Genuity downgraded Zimmer Biomet Holdings from a “buy” rating to a “hold” rating and decreased their price objective for the company from $141.00 to $135.00 in a report on Friday, July 28th. Finally, Piper Jaffray Companies reissued a “buy” rating and issued a $135.00 price objective on shares of Zimmer Biomet Holdings in a report on Friday, July 28th. Four investment analysts have rated the stock with a sell rating, seven have assigned a hold rating, fourteen have given a buy rating and one has given a strong buy rating to the stock. Zimmer Biomet Holdings has a consensus rating of “Hold” and an average price target of $133.71.
Shares of Zimmer Biomet Holdings (NYSE ZBH) traded down $1.13 on Tuesday, reaching $111.08. The company had a trading volume of 1,149,900 shares, compared to its average volume of 1,364,914. The company has a debt-to-equity ratio of 0.88, a current ratio of 1.47 and a quick ratio of 0.78. The firm has a market capitalization of $22,719.51, a P/E ratio of 13.90, a price-to-earnings-growth ratio of 1.74 and a beta of 1.17. Zimmer Biomet Holdings has a 52-week low of $98.20 and a 52-week high of $133.49.
Zimmer Biomet Holdings (NYSE:ZBH) last announced its quarterly earnings results on Wednesday, November 1st. The medical equipment provider reported $1.72 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $1.74 by ($0.02). The business had revenue of $1.82 billion during the quarter, compared to analyst estimates of $1.83 billion. Zimmer Biomet Holdings had a net margin of 8.36% and a return on equity of 16.29%. The business’s revenue for the quarter was down .8% compared to the same quarter last year. During the same period last year, the company earned $1.79 earnings per share. equities research analysts predict that Zimmer Biomet Holdings will post 8.03 EPS for the current fiscal year.
A number of large investors have recently added to or reduced their stakes in ZBH. Bronfman E.L. Rothschild L.P. raised its position in Zimmer Biomet Holdings by 25.3% in the second quarter. Bronfman E.L. Rothschild L.P. now owns 827 shares of the medical equipment provider’s stock worth $106,000 after acquiring an additional 167 shares in the last quarter. Parkside Financial Bank & Trust raised its position in Zimmer Biomet Holdings by 3.9% in the second quarter. Parkside Financial Bank & Trust now owns 872 shares of the medical equipment provider’s stock worth $112,000 after acquiring an additional 33 shares in the last quarter. Bank of Nova Scotia Trust Co. purchased a new position in Zimmer Biomet Holdings in the third quarter worth $112,000. FNY Managed Accounts LLC purchased a new position in Zimmer Biomet Holdings in the third quarter worth $117,000. Finally, BB&T Investment Services Inc. purchased a new position in Zimmer Biomet Holdings in the second quarter worth $144,000. Hedge funds and other institutional investors own 85.44% of the company’s stock.
Zimmer Biomet Holdings Company Profile
Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.
Receive News & Ratings for Zimmer Biomet Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.